Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult Subjects

NCT05526911 is registered in ClinicalTrials.gov with Global Alliance for TB Drug Development as lead sponsor.

NCT NCT05526911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05526911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult Subjects
Lead sponsor
Global Alliance for TB Drug Development
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2022
Completion date
September 26, 2022
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug sensitive tuberculosis, drug-resistant tuberculosis, multi drug resistant tuberculosis, mycobacterium tuberculosis infection, pulmonary disease, tuberculosis, tuberculosis, pulmonary